SLC5A2 and chronic kidney disease: In conclusion, SGLT-2 inhibitors, in the treatment of non-diabetic CKD, not only significantly delay kidney function deterioration through multiple mechanisms but also improve overall metabolic and cardiovascular health, enhancing patients’ quality of life and prognosis.